SPECIAL FEATURE - Artificial Intelligence in Drug Discovery, Development & Delivery
Contributor Cindy H. Dubin speaks with leading drug makers, device manufacturers, and contract organizations who dispel the myths around AI and Machine Learning in the pharma industry and share how they are using AI to streamline clinical trials, automate lab tests, optimize resource allocation, enhance development timelines, and improve patient-friendly dosage forms.
FORMULATION FORUM - Solid Oral Dosages: Controlled Release of Drugs
Shaukat Ali, PhD, and Jim Huang, PhD, review a few examples of controlled release excipients and their attributes from monolithic matrix tablets and polymeric coated tablets.
LEADERSHIP PANEL - Trends to Watch for in 2026
Contributor Cindy H. Dubin interviews life science leaders to discuss the role of AI in drug repurposing, the future of personalized medicine, the importance of sustainability, and how to keep pace with innovation amid real-time FDA reviews.
PREFILLABLE SYRINGE SYSTEM - Beyond Components: Designing Prefillable Syringe Systems to Streamline Success
Katie Falcone says prefillable syringes for biologics and vaccines can no longer be assembled as a set of parts; they must be treated as engineered systems with data, supply, and regulatory strategies built in from the start.
CONTROLLED RELEASE - Challenges in Consistent & Predictable Delivery of Drugs Using Oral Controlled Release Technologies
True Rogers, RPh, PhD, Matthias Knarr, PhD, and Mark Dreibelbis, PhD, say excipient selection is a key consideration within the QbD framework, particularly for CR technologies. Excipients must be chosen carefully to ensure they deliver the needed processability, quality, stability, and performance during and following the manufacture of dosage forms.
EXECUTIVE INTERVIEW - Incannex Healthcare: Pioneering the Future of Cannabinoid & Psychedelic Therapies
Joel Latham, CEO of Incannex Healthcare, shares how the company navigates complex global regulatory pathways, building strategic collaborations, and forging a path toward commercial success.
CELL & GENE THERAPY - What the Industry Can Learn From Baby KJ About Optimizing CRISPR Development
Venkata Indurthi, PhD, believes the success of Baby KJ provides a model that could be replicated many times over to treat people with ultra-rare genetic diseases.
PLATFORM TECHNOLOGY - How PolyPid’s PLEX Unlocks the Potential of Local & Prolonged Release
Dikla Czaczkes Akselbrad asks what if, instead of relying on systemic delivery, a platform could be created that anchors drugs directly at the site of need and controls its release over weeks or months?
MAB FORMULATION & FILL-FINISH - Obstacles in Monoclonal Antibody Formulation & Fill-Finish
Nandkumar Deorkar, PhD, explores some of the key challenges in mAb formulation and fill-finish, offering practical insights to help developers navigate complexity and ensure success.
EXECUTIVE INTERVIEW - CERo Therapeutics: A Novel Approach to Treating Cancer
Chris Ehrlich, CEO of CERo Therapeutics, discusses the company’s science, clinical program, the treatment landscape, and more.
MRNA THERAPEUTICS - Strategies for Enhanced Stability, Targeted Delivery & Safe Translation
Carsten Rudolph, PhD, explores many challenges and the solutions offered by novel technology platforms, providing insight into the evolving landscape of mRNA drug development and its potential as a future transformative modality.
2026 COMPANY PROFILES & CAPABILITIES
For each participating company, this section presents a detailed summary highlighting their core technologies, capabilities, technologies, and services.
PURIFICATION STRATEGIES - Purification at Scale: Overcoming Chromatography Challenges for Advanced Modalities
William Sanders, PhD, explores the real-world challenges of scaling chromatography and highlights how contract development and manufacturing organizations (CDMOs) can help partners overcome them.
DRUG DEVELOPMENT - Common CMC Pitfalls in Orphan Drug Development
Hibreniguss Terefe, PhD, says although the unique challenges of orphan drug development are amplified by compressed timelines and limited patient populations, common pitfalls also serve as cautionary tales for other areas of drug development.
3D PRINTING - The Future of 3D Printing in Pharma: Aprecia’s Vision for Transformative Medicine
Kyle Smith, MBA, explains how his company, a pioneer in pharmaceutical 3D printing, has a vision for distributed, patient-centric manufacturing that could re-shape the future of medicine.
EXPERT CONTENT & RESOURCES
Whether you're a researcher, a pharmaceutical professional, or simply interested in the latest advancements in drug development and delivery technology, you'll find a wealth of insightful expertise and current resources here.
Antibody Validation: The Hidden Key to Reproducible Drug Discovery
As research grows more complex and data-driven, rigorous antibody validation is increasingly recognized as a critical requirement for ensuring data integrity and improving the predictive power of drug discovery pipelines.
Klotho Neurosciences: Focused on Neurodegenerative & Age-Related Disorders
Dr. Joseph Sinkule, CEO of Klotho Neurosciences, discusses the company, its therapies, the human Klotho gene, and longevity.
Operational Excellence at Scale: Why Integrated Manufacturing is the Future Biopharmaceutical Standard
Pierre Catignol explains how the conventional model creates friction when the industry needs fluidity, and integrated manufacturing answers that call by converting logistical complexity into a reliable operating rhythm that clients trust.
Enabling a Breakthrough in Ophthalmology: A Case Study in Collaboration Between a Biotech & Device Manufacturer on a Novel Drug Delivery System
Ashwin Agarwal, CFO of Azura Ophthalmics and John Merhige, Co-CEO of Credence MedSystems, share an inside look at how two partners are aligning technical and regulatory strategies, integrating complementary expertise, and collaborating effectively to deliver an innovative ophthalmic combination product and inform future biotech–device partnerships.
Life Sciences in 2025: Strategic Recalibration & What's Next
Those who succeed in 2026 will be the organizations that set a bold vision, empower cross-functional collaboration, and stay committed to continuous innovation. The future of life sciences is one of extraordinary promise – and the recalibration underway today is setting the foundation for a healthier world tomorrow.
Have expert content to share? Contact us
EXCLUSIVE WHITEPAPERS
WHITE PAPER - Advancements in Intradermal Delivery: From Historic Techniques to Modern Innovations
This white paper explores the evolution of intradermal delivery methods, comparing historic methods of delivery such as the Mantoux technique with modern innovations such as the Terumo Immucise™ Intradermal Injection System.
WHITE PAPER - An Insoluble Problem? Overcoming Oral Drug Solubility Challenges With Functional Polymers
There are three key factors that need to be controlled when designing a drug product for solubility enhancement: the polymeric carrier; the manufacturing process; and the match to the desired API. By controlling these three factors bioavailability, drug release profile and manufacturability of your final drug product can be controlled.
WHITEPAPER - Drug Delivery – Recent Trends, Enabling Technologies, In-Vitro-In-Vivo Predictions & Personalized Medicine
Enabling technologies such as Nanotechnology, Amorphous Solid Dispersions, Self-emulsifying/nanoemulsifying drug delivery systems (SEDDS/SNEDDS) or Lipid Nano Particles (LNPs) for oral delivery are key elements for the development of complex and difficult to develop small molecules.
WHITEPAPER - 3D Reconstructed Skin Models: Transforming Clinical & Safety Testing
Targeted at researchers, toxicologists and formulation scientists in the clinical and dermatological fields, the white paper provides essential insights into how advanced in vitro skin and mucosal tissue systems are reshaping research and development practices.
WHITEPAPER - OXYCAPT™: Multilayer Plastic Vial: An Optimal Primary Container for Drug Products Transported With Dry Ice
OXYCAPT™ vial is the multilayer primary container with the distinctive structure that includes the gas barrier layer in the middle layer. They offer optimal features for the transport and storage of advanced therapeutics, such as cell and gene therapy products.
EXCLUSIVE WEBINARS
ON-DEMAND WEBINAR: Drug Product Design for Delivery of Challenging Molecules
In this talk we illustrate several case studies demonstrating how a fundamental understanding of molecular properties combined with a strategic vision for drug product design can lead to effective and advanceable formulations for even the most challenging drug products.
WEBINAR - Vytal: The RTU Snap-Fit System for Container Closure Solutions – Setting the Standard for the Future
In recent decades, the landscape of parenteral drug production has undergone significant transformation, driven by the emergence of novel molecules and advanced therapies. The pharmaceutical industry has witnessed a notable shift towards biologics, mAbs, and cell-based therapies, which now represent some of the most successful pharmaceutical products globally.
WEBINAR ON DEMAND: Precision at Scale: Enabling Novel Therapeutics With Nanoparticle Manufacturing
Watch this on-demand webinar to learn about the key steps and considerations in bringing novel nanoparticle-based therapeutics from early R&D to commercial stages. Drawing from our 20 years of experience in the CDMO space, we cover critical topics unique to nanomaterials…..
WEBINAR: Introducing Key Concepts in Tableting Research: Unleashing Essential Concepts and Strategies for Enhanced Formulation Development
Tableting can present a series of challenges, particularly when dealing with formulations that have poor flowability, low compressibility, or high cohesivity. These issues can lead to manufacturing inefficiencies….
WEBINAR ON DEMAND: Advantages of Carbopol® Polymers in Oral Formulations
In this video, the Lubrizol team together with the IMCD US team takes you through formulation aspects of Carbopol® polymers as well as the results of a case study on an Acetaminophen oral suspension formulation.
MARKET NEWS & TRENDS
Neomorph Announces First Patient Dosed in Phase 1/2 Trial Evaluating the Treatment of Locally Advanced or Metastatic Non-Resectable Clear Cell Renal Cell Carcinoma
Neomorph, Inc. recently announced the first patient has been dosed in the Phase 1/2 clinical trial (NCT07300241) evaluating NEO-811, a novel investigational molecular glue degrader, in…
Quanterix Announces FDA 510(k) Submission for a Multi-Analyte Algorithmic Blood Test for Alzheimer’s Disease Detection
Quanterix Corporation recently announced it has submitted a 510(k) premarket notification to the US FDA for a multi-analyte algorithmic blood test for Alzheimer’s disease (AD).…
Cellares to Expand Automated Manufacturing to Gene-Edited Stem Cell Therapies
Cellares recently announced a collaboration with the Stanford Center for Definitive and Curative Medicine (CDCM) and Stanford Innovative Medicines Accelerator (IMA) to automate manufacturing and…
Alzheon Reports Plasma Biomarker Results From Phase 3 & 2 Studies, Validating First-in-Class Mechanism of Action & Underscoring Benefits in Cognition, Function & Brain Volume Protection in Alzheimer’s Patients
Alzheon, Inc. recently announced plasma biomarker analyses from its APOLLOE4 Phase 3 and Phase 2 clinical studies of valiltramiprosate/ALZ-801. New results offer robust evidence supporting the…
Sanofi’s Venglustat Met All Primary Endpoints in Phase 3 Study of Type 3 Gaucher Disease
Positive results from the LEAP2MONO Phase 3 study (clinical study identifier: NCT05222906) demonstrated that venglustat met the primary and three out of four key secondary…
MGS Launches A.i.r. Platform, Delivering New Levels of Design Flexibility for Auto-Injectors
MGS recently announced the launch of the A.i.r. Platform, a groundbreaking customizable auto-injector platform designed to meet the diverse needs of patients, Pharmaceutical innovators and…
Piramal Pharma Solutions Introduces Tablet-in-Capsule Capabilities
Piramal Pharma Solutions recently announce the successful development, scale-up, and commercialization of a tablet-in-capsule drug delivery system at its drug product facilities in Pithampur and Ahmedabad,…
PhaseV Launches AI-Powered Enrollment Lab: Eliminating Guesswork & Grounding Study Design in Clinical Reality
PhaseV recently announced the launch of its new Enrollment Lab solution at the 17th Annual SCOPE Summit. A high-impact addition to the PhaseV ClinOps platform, this…
Ardena Completes Divestment of its Södertälje Drug Substance Site in Sweden to Nanologica
Ardena recently announced it has completed the divestment of its drug substance (API) site in Södertälje, Sweden, to Nanologica AB. The business will operate as…
Vetter Pharma to Build New Manufacturing Site in Germany
Vetter Pharma has confirmed its plans to build a state-of-the-art production facility in the Saarland region of southwest Germany. This strategic investment marks a significant…
ENA Respiratory Announces Dosing of First Participants in Phase II Study of Nasal Spray Designed to Protect Against Symptomatic Viral Respiratory Infections
ENA Respiratory recently announced it has dosed the first participants in its Phase II community study of INNA-051, (with the first participant dosing now completed).…
Boehringer Ingelheim’s Investigational Asset Delivers Proteinuria Reduction in Phase II Kidney Trial
Boehringer Ingelheim today announced results from a 12-week Phase II clinical trial evaluating apecotrep (BI 764198), an oral, potential first-in-class, non-immunosuppressive TRPC6 inhibitor for people…
Halo Pharma to Become a Stand-Alone Drug Product Contract Development & Manufacturing Organization
Halo Pharma, a leading CDMO specializing in drug product pharmaceutical development and manufacturing services, will become a stand-alone business as a result of the sale…
Argo Biopharma Announces First Patient Dosed in Phase 2b Trial of siRNA Therapeutic in Patients with Elevated Lp(a)
Argo Biopharmaceutical Co., Ltd. recently announced the first patient has been dosed in a global Phase 2b clinical trial sponsored by Novartis evaluating DII235, also…
Vortex Biotech Opens New State-of-the-Art Laboratory at Manchester Science Park
Vortex Biotech Holdings Limited has announced the opening of its advanced laboratory facilities at Manchester Science Park. The new site significantly enhances the company’s R&D…
Nanexa Announces Breakthrough Preclinical Data Demonstrating Exceptional Pharmacokinetic Profile for Monthly Semaglutide Formulation
Nanexa AB recently announced exceptional preclinical results for its long-acting semaglutide formulation developed using the company’s proprietary PharmaShell drug delivery platform. PharmaShell encases active pharmaceutical…
iXCells Biotechnologies & Rosebud Biosciences Partner to Advance Organoid-Based Models for Rare Diseases
iXCells Biotechnologies and Rosebud Biosciences recently announced a partnership to develop a personalized, human-based approach for predicting drug safety and informing translational decision-making in rare…
Medicus Pharma Announces Amendment to LifeArc License Improving Teverelix Long-Term Economic & Development Profile
Medicus Pharma Ltd. recently announced its subsidiary, Antev Ltd., has entered into Amendment No. 3 to its license agreement with LifeArc relating to Teverelix, an investigational next generation long-acting GnRH…
Dosing Completed in the Phase I Clinical Trial of PulseSight Therapeutics’ Treatment for Dry AMD/Geographic Atrophy
PulseSight Therapeutics SAS recently announced the completion of PST-611 Phase I clinical trial enrolment. Trial data will be presented at the 2026 ARVO Annual Meeting…
Mendra Launches With $82 Million to Acquire, Develop & Commercialize Therapeutics for High Unmet Need Rare Diseases
Mendra, Inc. recently announced its launch in conjunction with the closing of an $82 million oversubscribed Series A financing. The round was co-led by OrbiMed, 8VC,…
